1-2 of 2
tablets, enteric-coated
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)

Owen A. O'Connor, MD PhD, Muhit Özcan, MD, Eric D. Jacobsen, MD, Josep Maria Roncero Vidal, MD, Judith Trotman, MBChB, Judit Demeter, MD PhD DsC, Tamás Masszi, MD, Juliana Pereira, MD PhD, Radhakrishnan Ramchandren, MD, Francesco A. d'Amore, MD PhD, Francine Foss, MD, Won-Seog Kim, MD PhD, John P. Leonard, MD, Carlos Sérgio Chiattone, MD PhD, Pier Luigi Zinzani, MD PhD, Hua Liu, PhD, JungAh Jung, PhD, Xiaofei Zhou, PhD, E. Jane Leonard, MSc, Claudio Dansky Ullmann, MD, Andrei R. Shustov, MD
Journal: Blood
Blood (2015) 126 (23): 341.
https://doi.org/10.1182/blood.V126.23.341.341
Published: 2015
Journal Articles

Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237)–An Investigational Aurora A Kinase Inhibitor–in Patients with Advanced Hematologic Malignancies

Kevin R. Kelly, MD, Swaminathan Padmanabhan, MBBS, MD, André Goy, MD, Jesus G. Berdeja, MD, Craig B. Reeder, MD, Kevin T. McDonagh, MD, Xiaofei Zhou, PhD, Hadi Danaee, SD, Hugh Xiao, PhD, Ely Benaim, MD, Thomas C. Shea, MD
Journal: Blood
Blood (2011) 118 (21): 2477.
https://doi.org/10.1182/blood.V118.21.2477.2477
Published: 2011